Variants in the DDX6-CXCR5 autoimmune disease risk locus influence the regulatory network in immune cells and salivary gland

doi:10.1016/j.ard.2025.04.023

. 2025 May 29:S0003-4967(25)00949-5.

doi: 10.1016/j.ard.2025.04.023. Online ahead of print.

Variants in the DDX6-CXCR5 autoimmune disease risk locus influence the regulatory network in immune cells and salivary gland

Mandi M Wiley¹, Marcin Radziszewski², Bhuwan Khatri¹, Michelle L Joachims³, Kandice L Tessneer¹, Anna M Stolarczyk¹, Songyuan Yao¹, James Li², Cherilyn Pritchett-Frazee¹, Audrey A Johnston⁴, Astrid Rasmussen¹, Juan-Manuel Anaya⁵, Lara A Aqrawi⁶, Sang-Cheol Bae⁷, Eva Baecklund⁸, Albin Björk⁹, Johan G Brun¹⁰, Sara Magnusson Bucher¹¹, Nick Dand¹², Maija-Leena Eloranta⁸, Fiona Engelke¹³, Helena Forsblad-d'Elia¹⁴, Cecilia Fugmann⁸, Stuart B Glenn¹, Chen Gong¹², Jacques-Eric Gottenberg¹⁵, Daniel Hammenfors¹⁰, Juliana Imgenberg-Kreuz⁸, Janicke Liaaen Jensen¹⁶, Svein Joar Auglænd Johnsen¹⁷, Malin V Jonsson¹⁸, Jennifer A Kelly¹, Sharmily Khanam⁴, Kwangwoo Kim¹⁹, Marika Kvarnström²⁰, Thomas Mandl²¹, Javier Martín²², David L Morris¹², Gaetane Nocturne²³, Katrine Brække Norheim²⁴, Peter Olsson²¹, Øyvind Palm²⁵, Jacques-Olivier Pers²⁶, Nelson L Rhodus²⁷, Christopher Sjöwall²⁸, Kathrine Skarstein¹⁰, Kimberly E Taylor²⁹, Phil Tombleson³⁰, Gudny Ella Thorlacius⁹, Swamy R Venuturupalli³¹, Edward M Vital³², Daniel J Wallace³¹, Lida Radfar³³, Michael T Brennan³⁴, Judith A James³⁵, R Hal Scofield³⁶, Patrick M Gaffney², Lindsey A Criswell³⁷, Roland Jonsson¹⁸, Silke Appel¹⁸, Per Eriksson²⁸, Simon J Bowman³⁸, Roald Omdal²⁴, Lars Rönnblom⁸, Blake M Warner³⁹, Maureen Rischmueller⁴⁰, Torsten Witte¹³, A Darise Farris³⁵, Xavier Mariette²³, Caroline H Shiboski²⁹; Sjögren’s International Collaborative Clinical Alliance (SICCA); Marie Wahren-Herlenius⁴¹, Marta E Alarcón-Riquelme⁴²; PRECISESADS Clinical Consortium; Wan-Fai Ng⁴³; UK Primary Sjögren’s Syndrome Registry; Kathy L Sivils⁴, Joel M Guthridge³⁵, Indra Adrianto⁴⁴, Timothy J Vyse¹², Betty P Tsao⁴⁵, Gunnel Nordmark⁸, Christopher J Lessard⁴⁶

Affiliations

¹ Genes and Human Disease Research Program, Oklahoma Medical Research Foundation (OMRF), Oklahoma City, OK, USA.
² Genes and Human Disease Research Program, Oklahoma Medical Research Foundation (OMRF), Oklahoma City, OK, USA; University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
³ Genes and Human Disease Research Program, Oklahoma Medical Research Foundation (OMRF), Oklahoma City, OK, USA; Arthritis and Clinical Immunology Research Program, OMRF, Oklahoma City, OK, USA.
⁴ Arthritis and Clinical Immunology Research Program, OMRF, Oklahoma City, OK, USA.
⁵ Universidad de la Costa, Barranquilla, Colombia.
⁶ Kristiania University College, Oslo, Norway; University of Oslo, Oslo, Norway.
⁷ Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Hanyang University Institute for Rheumatology Research and Hanyang Institute of Bioscience and Biotechnology, Seoul, Republic of Korea.
⁸ Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
⁹ Karolinska Institutet, Stockholm, Sweden.
¹⁰ Haukeland University Hospital, Bergen, Norway; Broegelmann Research Laboratory, Department of Clinical Sciences, University of Bergen, Bergen, Norway.
¹¹ Örebro University, Örebro, Sweden.
¹² Department of Medical and Molecular Genetics, School of Basic and Medical Biosciences, King's College London, London, UK.
¹³ Hannover Medical School, Hannover, Germany.
¹⁴ University of Gothenburg, Gothenburg, Sweden; Umeå Universitet, Umeå, Sweden.
¹⁵ Hôspitaux Universitaires de Strasbourg, Strasbourg, France; Université de Strasbourg, Strasbourg, France; Regenerative NanoMedicine, Institut National de la Santé et de la Recherche Médicale (INSERM), Strasbourg, France.
¹⁶ University of Oslo, Oslo, Norway.
¹⁷ Stavanger University Hospital, Stavanger, Norway.
¹⁸ Broegelmann Research Laboratory, Department of Clinical Sciences, University of Bergen, Bergen, Norway.
¹⁹ Kyung Hee University, Seoul, Republic of Korea.
²⁰ Karolinska Institutet, Stockholm, Sweden; Academic Specialist Center, Center for Rheumatology, Stockholm Health Services, Stockholm, Sweden.
²¹ Skane University Hospital Malmö, Lund University, Malmö, Sweden.
²² Instituto de Parasitología y Biomedicina López-Neyra, CSIC, Granada, Spain.
²³ Université Paris-Saclay, Le Kremlin Bicêtre, Paris, France; Assistance Publique - Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, Paris, France.
²⁴ Broegelmann Research Laboratory, Department of Clinical Sciences, University of Bergen, Bergen, Norway; Stavanger University Hospital, Stavanger, Norway.
²⁵ Oslo University Hospital, Oslo, Norway.
²⁶ LBAI, UMR1227, University of Brest, INSERM, Brest, France; CHU de Brest, Brest, France.
²⁷ University of Minnesota, Minneapolis, MN, USA.
²⁸ Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden.
²⁹ University of California San Francisco, San Francisco, CA, USA.
³⁰ Department of Medical and Molecular Genetics, School of Basic and Medical Biosciences, King's College London, London, UK; NIHR GSTFT/KCL Biomedical Research Centre, London, UK.
³¹ Cedars-Sinai Medical Center, Los Angeles, CA, USA.
³² Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; NIHR Leeds Musculoskeletal Biomedical Research Centre, Leeds Teaching Hospital NHS Trust, Leeds, UK.
³³ College of Dentistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
³⁴ Atrium Health Carolinas Medical Center, Charlotte, NC, USA; Wake Forest University School of Medicine, Winston-Salem, NC, USA.
³⁵ University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; Arthritis and Clinical Immunology Research Program, OMRF, Oklahoma City, OK, USA.
³⁶ University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; Arthritis and Clinical Immunology Research Program, OMRF, Oklahoma City, OK, USA; US Department of Veteran Affairs Medical Center, Oklahoma City, OK, USA.
³⁷ University of California San Francisco, San Francisco, CA, USA; National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.
³⁸ University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
³⁹ Salivary Disorders Unit and NIDCR Sjögren's Disease Clinic, National Institute of Dental and Craniofacial Research, Bethesda, MD, USA.
⁴⁰ The Queen Elizabeth Hospital and Medical School, University of Adelaide, SA, Australia.
⁴¹ Karolinska Institutet, Stockholm, Sweden; Broegelmann Research Laboratory, Department of Clinical Sciences, University of Bergen, Bergen, Norway.
⁴² Karolinska Institutet, Stockholm, Sweden; GENYO, Center for Genomics and Oncological Research Pfizer/University of Granada/Andalusian Regional Government, Granada, Spain.
⁴³ NIHR Newcastle Biomedical Research Centre and NIHR Newcastle Clinical Research Facility, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK; Translational and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne, UK; University College Cork, Cork, Ireland.
⁴⁴ Henry Ford Health, Detroit, MI, USA; Michigan State University, East Lansing, MI, USA; Henry Ford Health + Michigan State University Health Sciences, East Lansing, MI, USA.
⁴⁵ Medical University of South Carolina, Charleston, SC, USA.
⁴⁶ Genes and Human Disease Research Program, Oklahoma Medical Research Foundation (OMRF), Oklahoma City, OK, USA; University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA. Electronic address: chris-lessard@omrf.org.

PMID: 40447495
PMCID: PMC12236377 (available on 2026-05-29)
DOI: 10.1016/j.ard.2025.04.023

Variants in the DDX6-CXCR5 autoimmune disease risk locus influence the regulatory network in immune cells and salivary gland

Mandi M Wiley et al. Ann Rheum Dis. 2025.

. 2025 May 29:S0003-4967(25)00949-5.

doi: 10.1016/j.ard.2025.04.023. Online ahead of print.

Authors

Affiliations

¹ Genes and Human Disease Research Program, Oklahoma Medical Research Foundation (OMRF), Oklahoma City, OK, USA.
² Genes and Human Disease Research Program, Oklahoma Medical Research Foundation (OMRF), Oklahoma City, OK, USA; University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
³ Genes and Human Disease Research Program, Oklahoma Medical Research Foundation (OMRF), Oklahoma City, OK, USA; Arthritis and Clinical Immunology Research Program, OMRF, Oklahoma City, OK, USA.
⁴ Arthritis and Clinical Immunology Research Program, OMRF, Oklahoma City, OK, USA.
⁵ Universidad de la Costa, Barranquilla, Colombia.
⁶ Kristiania University College, Oslo, Norway; University of Oslo, Oslo, Norway.
⁷ Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Hanyang University Institute for Rheumatology Research and Hanyang Institute of Bioscience and Biotechnology, Seoul, Republic of Korea.
⁸ Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
⁹ Karolinska Institutet, Stockholm, Sweden.
¹⁰ Haukeland University Hospital, Bergen, Norway; Broegelmann Research Laboratory, Department of Clinical Sciences, University of Bergen, Bergen, Norway.
¹¹ Örebro University, Örebro, Sweden.
¹² Department of Medical and Molecular Genetics, School of Basic and Medical Biosciences, King's College London, London, UK.
¹³ Hannover Medical School, Hannover, Germany.
¹⁴ University of Gothenburg, Gothenburg, Sweden; Umeå Universitet, Umeå, Sweden.
¹⁵ Hôspitaux Universitaires de Strasbourg, Strasbourg, France; Université de Strasbourg, Strasbourg, France; Regenerative NanoMedicine, Institut National de la Santé et de la Recherche Médicale (INSERM), Strasbourg, France.
¹⁶ University of Oslo, Oslo, Norway.
¹⁷ Stavanger University Hospital, Stavanger, Norway.
¹⁸ Broegelmann Research Laboratory, Department of Clinical Sciences, University of Bergen, Bergen, Norway.
¹⁹ Kyung Hee University, Seoul, Republic of Korea.
²⁰ Karolinska Institutet, Stockholm, Sweden; Academic Specialist Center, Center for Rheumatology, Stockholm Health Services, Stockholm, Sweden.
²¹ Skane University Hospital Malmö, Lund University, Malmö, Sweden.
²² Instituto de Parasitología y Biomedicina López-Neyra, CSIC, Granada, Spain.
²³ Université Paris-Saclay, Le Kremlin Bicêtre, Paris, France; Assistance Publique - Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, Paris, France.
²⁴ Broegelmann Research Laboratory, Department of Clinical Sciences, University of Bergen, Bergen, Norway; Stavanger University Hospital, Stavanger, Norway.
²⁵ Oslo University Hospital, Oslo, Norway.
²⁶ LBAI, UMR1227, University of Brest, INSERM, Brest, France; CHU de Brest, Brest, France.
²⁷ University of Minnesota, Minneapolis, MN, USA.
²⁸ Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden.
²⁹ University of California San Francisco, San Francisco, CA, USA.
³⁰ Department of Medical and Molecular Genetics, School of Basic and Medical Biosciences, King's College London, London, UK; NIHR GSTFT/KCL Biomedical Research Centre, London, UK.
³¹ Cedars-Sinai Medical Center, Los Angeles, CA, USA.
³² Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; NIHR Leeds Musculoskeletal Biomedical Research Centre, Leeds Teaching Hospital NHS Trust, Leeds, UK.
³³ College of Dentistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
³⁴ Atrium Health Carolinas Medical Center, Charlotte, NC, USA; Wake Forest University School of Medicine, Winston-Salem, NC, USA.
³⁵ University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; Arthritis and Clinical Immunology Research Program, OMRF, Oklahoma City, OK, USA.
³⁶ University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; Arthritis and Clinical Immunology Research Program, OMRF, Oklahoma City, OK, USA; US Department of Veteran Affairs Medical Center, Oklahoma City, OK, USA.
³⁷ University of California San Francisco, San Francisco, CA, USA; National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.
³⁸ University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
³⁹ Salivary Disorders Unit and NIDCR Sjögren's Disease Clinic, National Institute of Dental and Craniofacial Research, Bethesda, MD, USA.
⁴⁰ The Queen Elizabeth Hospital and Medical School, University of Adelaide, SA, Australia.
⁴¹ Karolinska Institutet, Stockholm, Sweden; Broegelmann Research Laboratory, Department of Clinical Sciences, University of Bergen, Bergen, Norway.
⁴² Karolinska Institutet, Stockholm, Sweden; GENYO, Center for Genomics and Oncological Research Pfizer/University of Granada/Andalusian Regional Government, Granada, Spain.
⁴³ NIHR Newcastle Biomedical Research Centre and NIHR Newcastle Clinical Research Facility, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK; Translational and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne, UK; University College Cork, Cork, Ireland.
⁴⁴ Henry Ford Health, Detroit, MI, USA; Michigan State University, East Lansing, MI, USA; Henry Ford Health + Michigan State University Health Sciences, East Lansing, MI, USA.
⁴⁵ Medical University of South Carolina, Charleston, SC, USA.
⁴⁶ Genes and Human Disease Research Program, Oklahoma Medical Research Foundation (OMRF), Oklahoma City, OK, USA; University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA. Electronic address: chris-lessard@omrf.org.

PMID: 40447495
PMCID: PMC12236377 (available on 2026-05-29)
DOI: 10.1016/j.ard.2025.04.023

Abstract

Objectives: Sjögren's disease (SjD) and systemic lupus erythematosus (SLE) share genetic risk at the DDX6-CXCR5 locus (11q23.3). Identifying and functionally characterising shared SNPs spanning this locus can provide new insights into common genetic mechanisms of autoimmunity.

Methods: Transdisease meta-analyses, fine-mapping, and bioinformatic analyses prioritised shared likely functional single nucleotide polymorphisms (SNPs) for allele-specific and cell type-specific functional interrogation using electromobility shift, luciferase reporter, and quantitative chromatin conformation capture assays and clustered regularly interspaced short palindromic repeat (CRISPR) gene regulation.

Results: Five shared SNPs were identified as likely functional in primary human immune cells, salivary gland and kidney tissues: rs57494551, rs4936443, rs4938572, rs7117261, and rs4938573. All 5 SNPs exhibited cell type-specific and allele-specific effects on nuclear protein binding affinity and enhancer/promoter regulatory activity in immune, salivary gland epithelial, and kidney epithelial cell models. Mapping of chromatin-chromatin interactions revealed a chromatin regulatory network that expanded beyond DDX6 and CXCR5 to include PHLDB1, lnc-PHLDB1-1, BCL9L, TRAPPC4, among others. Coalescence of functional assays and multiomic data analyses indicated that these SNPs likely modulate the activity of 3 regulatory regions: intronic rs57494551 regulatory region, intergenic SNP haplotype (rs4938572, rs4936443, and rs7117261) regulatory region, and rs4938573 regulatory region upstream of the CXCR5 promoter.

Conclusions: Shared genetic susceptibly at the DDX6-CXCR5 locus in SjD and SLE likely alters common mechanisms of autoimmunity, including interferon signalling (DDX6), autophagy (TRAPPC4), and lymphocytic infiltration of disease-target tissues (CXCR5). Further, using multiomic data from patients with SjD, combined with bioinformatic and in vitro functional studies, can provide mechanistic insights into how genetic risk influences the biological pathways that drive complex autoimmunity.

PubMed Disclaimer

Conflict of interest statement

Competing interests AR received consulting fees from Immunovant and Clinical Outcomes Solutions. ND received a teaching honorarium from the British Association of Dermatologists. JLJ received travel support from the University of Oslo. MVJ received travel support from the International Symposium for Sjögren’s Syndrome 2022 and serves as a members’ representative for the Journal of the Norwegian Dental Association (Tidende). SK is currently employed at Beckman Coulter Inc. TM is currently employed by UCB Pharma. GNoc received consulting fees from Abbvie, Novartis, Galapagos, and Amgen and travel support from Amgen and UCB and is a member of the Boehringer Ingelheim Advisory Board. PO received consulting fees from UCB and Lilly and a speaker honorarium from the Internetmedicin.se (website). CS is employed as Director, CAR-T Immunology European Medical Engagement Lead, at Bristol-Myers-Squib (since April 2024); received speaker honorariums from AstraZeneca, Novartis, and Bristol-Myers Squibb; and is a member of the Fresenius Kabi Advisory Board. GET is employed by DeCODE genetics/Amgen Inc. SRV served on the American College of Rheumatology Board of Governors and has received research support from Navidea Biopharmaceuticals Inc, ARGENX, Mallinckrodt, Janssen, and Kiniksa Pharmaceuticals. EMV received research support from AstraZeneca; consulting fees from AstraZeneca, UCB, Otsuka, Abbvie, Novartis, Aurinia, and Pfizer; and payment for expert testimony from the National Institute of Health and Clinical Excellence and serves as a member of the Aurinia Data Safety and Monitoring Board, General Secretary of SLEuro, and Chair of BILAG. MTB received research support and consulting fees from Meira GTx, Lipella, and Sun Pharmaceuticals and travel support from the North Carolina Dental Society. JAJ received research support from the National Institutes of Health and Progentec Biosciences and consulting fees from GSK and Novartis. RHS is a consultant for Johnson & Johnson Innovative Medicine and Merk Pharmaceuticals, served on a clinical trial advisory board for Janssen Pharmaceuticals, and served on the IQVIA data safety and monitoring board for a clinical trial in Sjögren’s disease. SJB served on advisory boards and received consulting fees and travel support in the past 3 years from Abbvie, Amgen, Argenx, Artivabio, Aurinia, Bain, BMS, EcoR1, IQVIA, J&J, Kiniksa, Novartis, and Scitaris. LR received consulting fees and speaker honorarium form AstraZeneca. BMW has active collaborative research agreements with Astellas Bio and Pfizer Inc. MR received grants from Amgen, Argenx, AstraZeneca, Bristol Myers-Squibb, Horizon Therapeutics, Novartis, and Servier for clinical trials in Sjögren’s syndrome and SLE. TW received consulting fees from AbbVie, Boehringer Ingelheim, Fresenius Kabi, Galapagos, Janssen, Lilly, and Novartis; speaker honorariums from those listed plus Amgen, AstraZeneca, Chugai, GSK, Medac, Nordic, Sanofi, and UCB; and travel support from AbbVie, Janssen, Lilly, and UCB. ADF received research support from Johnson & Johnson Innovative Medicine (formerly Janssen; ended December 31, 2023). XM received consulting fees from BMS, GSK, Janssen, Novartis, Otsuka, and Pfizer. MEA-R has an active research collaboration with Sanofi, GSK, Novartis, Astra Zeneca, Janssen, and BMS; has received funding from Sanofi and BMS; and has received consulting fees from GSK. W-FN provided consulting services for Novartis, BMS, Janssen, Sanofi, Abbvie, IQVIA, Argenx, and Resolve Therapeutics. KLS currently employed by Johnson & Johnson Innovative Medicine. CJL received research support from Johnson & Johnson Innovative Medicine (formerly Janssen; ended December 31, 2023); consulting fees from Janssen Global Servicers, and served as a member for the Johnson and Johnson Sjögren’s Disease Advisory Board. All other authors declared no conflicts of interest.

Update of

Variants in the DDX6-CXCR5 autoimmune disease risk locus influence the regulatory network in immune cells and salivary gland.
Wiley MM, Khatri B, Joachims ML, Tessneer KL, Stolarczyk AM, Rasmussen A, Anaya JM, Aqrawi LA, Bae SC, Baecklund E, Björk A, Brun JG, Bucher SM, Dand N, Eloranta ML, Engelke F, Forsblad-d'Elia H, Fugmann C, Glenn SB, Gong C, Gottenberg JE, Hammenfors D, Imgenberg-Kreuz J, Jensen JL, Johnsen SJA, Jonsson MV, Kelly JA, Khanam S, Kim K, Kvarnström M, Mandl T, Martín J, Morris DL, Nocturne G, Norheim KB, Olsson P, Palm Ø, Pers JO, Rhodus NL, Sjöwall C, Skarstein K, Taylor KE, Tombleson P, Thorlacius GE, Venuturupalli S, Vital EM, Wallace DJ, Grundahl KM, Radfar L, Brennan MT, James JA, Scofield RH, Gaffney PM, Criswell LA, Jonsson R, Appel S, Eriksson P, Bowman SJ, Omdal R, Rönnblom L, Warner BM, Rischmueller M, Witte T, Farris AD, Mariette X, Shiboski CH; Sjögren’s International Collaborative Clinical Alliance (SICCA); Wahren-Herlenius M, Alarcón-Riquelme ME; PRECISESADS Clinical Consortium; Ng WF; UK Primary Sjögren’s Syndrome Registry; Sivils KL, Guthridge JM, Adrianto I, Vyse TJ, Tsao BP, Nordmark G, Lessard CJ. Wiley MM, et al. bioRxiv [Preprint]. 2023 Oct 6:2023.10.05.561076. doi: 10.1101/2023.10.05.561076. bioRxiv. 2023. Update in: Ann Rheum Dis. 2025 May 29:S0003-4967(25)00949-5. doi: 10.1016/j.ard.2025.04.023. PMID: 39071447 Free PMC article. Updated. Preprint.

References

1. Thorlacius GE, Bjork A, Wahren-Herlenius M. Genetics and epigenetics of primary Sjogren syndrome: implications for future therapies. Nat Rev Rheumatol. 2023;19(5):288–306. - PMC - PubMed
1. Guga S, Wang Y, Graham DC, Vyse TJ. A review of genetic risk in systemic lupus erythematosus. Expert Rev Clin Immunol. 2023;19(10):1247–58. - PubMed
1. Ortiz-Fernandez L, Martin J, Alarcon-Riquelme ME. A Summary on the Genetics of Systemic Lupus Erythematosus, Rheumatoid Arthritis, Systemic Sclerosis, and Sjogren’s Syndrome. Clin Rev Allergy Immunol. 2023;64(3):392–411. - PubMed
1. Paredes JL, Fernandez-Ruiz R, Niewold TB. T Cells in Systemic Lupus Erythematosus. Rheum Dis Clin North Am. 2021;47(3):379–93. - PMC - PubMed
1. Rios-Rios WJ, Sosa-Luis SA, Torres-Aguilar H. T Cells Subsets in the Immunopathology and Treatment of Sjogren’s Syndrome. Biomolecules. 2020;10(11). - PMC - PubMed

Grants and funding

LinkOut - more resources

Full Text Sources
- Elsevier Science

[1] Thorlacius GE, Bjork A, Wahren-Herlenius M. Genetics and epigenetics of primary Sjogren syndrome: implications for future therapies. Nat Rev Rheumatol. 2023;19(5):288–306. - PMC - PubMed

[2] Thorlacius GE, Bjork A, Wahren-Herlenius M. Genetics and epigenetics of primary Sjogren syndrome: implications for future therapies. Nat Rev Rheumatol. 2023;19(5):288–306. - PMC - PubMed

[3] Guga S, Wang Y, Graham DC, Vyse TJ. A review of genetic risk in systemic lupus erythematosus. Expert Rev Clin Immunol. 2023;19(10):1247–58. - PubMed

[4] Guga S, Wang Y, Graham DC, Vyse TJ. A review of genetic risk in systemic lupus erythematosus. Expert Rev Clin Immunol. 2023;19(10):1247–58. - PubMed

[5] Ortiz-Fernandez L, Martin J, Alarcon-Riquelme ME. A Summary on the Genetics of Systemic Lupus Erythematosus, Rheumatoid Arthritis, Systemic Sclerosis, and Sjogren’s Syndrome. Clin Rev Allergy Immunol. 2023;64(3):392–411. - PubMed

[6] Ortiz-Fernandez L, Martin J, Alarcon-Riquelme ME. A Summary on the Genetics of Systemic Lupus Erythematosus, Rheumatoid Arthritis, Systemic Sclerosis, and Sjogren’s Syndrome. Clin Rev Allergy Immunol. 2023;64(3):392–411. - PubMed

[7] Paredes JL, Fernandez-Ruiz R, Niewold TB. T Cells in Systemic Lupus Erythematosus. Rheum Dis Clin North Am. 2021;47(3):379–93. - PMC - PubMed

[8] Paredes JL, Fernandez-Ruiz R, Niewold TB. T Cells in Systemic Lupus Erythematosus. Rheum Dis Clin North Am. 2021;47(3):379–93. - PMC - PubMed

[9] Rios-Rios WJ, Sosa-Luis SA, Torres-Aguilar H. T Cells Subsets in the Immunopathology and Treatment of Sjogren’s Syndrome. Biomolecules. 2020;10(11). - PMC - PubMed

[10] Rios-Rios WJ, Sosa-Luis SA, Torres-Aguilar H. T Cells Subsets in the Immunopathology and Treatment of Sjogren’s Syndrome. Biomolecules. 2020;10(11). - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Variants in the DDX6-CXCR5 autoimmune disease risk locus influence the regulatory network in immune cells and salivary gland

Affiliations

Variants in the DDX6-CXCR5 autoimmune disease risk locus influence the regulatory network in immune cells and salivary gland

Authors

Affiliations

Abstract

Conflict of interest statement

Update of

References

Grants and funding

LinkOut - more resources

Full Text Sources

Abstract

Conflict of interest statement

Update of

References

Related information

Grants and funding

LinkOut - more resources

Full Text Sources